How to buy Codexis stock | 15.85

Codexis, Inc is a biotechnology business based in the US. Codexis shares (CDXS) are listed on the NASDAQ and all prices are listed in US Dollars. Codexis employs 161 staff and has a trailing 12-month revenue of around USD$70.2 million.

How to buy shares in Codexis

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Codexis. Find the stock by name or ticker symbol: CDXS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Codexis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$15.85, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Codexis, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Codexis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Codexis's share price?

Since the stock market crash in March caused by coronavirus, Codexis's share price has had significant positive movement.

Its last market close was USD$15.85, which is 11.67% up on its pre-crash value of USD$14 and 88.02% up on the lowest point reached during the March crash when the shares fell as low as USD$8.43.

If you had bought USD$1,000 worth of Codexis shares at the start of February 2020, those shares would have been worth USD$622.33 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$989.36.

Codexis share price

Use our graph to track the performance of CDXS stocks over time.

Codexis shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$15.85
52-week range	USD$8.43 - USD$18.87
50-day moving average	USD$12.5979
200-day moving average	USD$12.0159
Wall St. target price	USD$18.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.26

Buy Codexis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Codexis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Codexis, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Codexis price performance over time

Historical closes compared with the close of $15.85 from 2020-11-16

1 week (2020-11-18)	-2.40%
1 month (2020-10-23)	9.92%
3 months (2020-08-25)	18.64%
6 months (2020-05-22)	41.39%

1 year (2019-11-25)	0.96%
2 years (2018-11-23)	-12.19%
3 years (2017-11-24)	153.60%
5 years (2015-11-25)	311.69%

Codexis financials

Revenue TTM	USD$70.2 million
Gross profit TTM	USD$19 million
Return on assets TTM	-6.33%
Return on equity TTM	-14.77%
Profit margin	-20.36%
Book value	$1.603
Market capitalisation	USD$843.1 million

TTM: trailing 12 months

Shorting Codexis shares

There are currently 4.8 million Codexis shares held short by investors – that's known as Codexis's "short interest". This figure is 3.8% up from 4.6 million last month.

There are a few different ways that this level of interest in shorting Codexis shares can be evaluated.

Codexis's "short interest ratio" (SIR)

Codexis's "short interest ratio" (SIR) is the quantity of Codexis shares currently shorted divided by the average quantity of Codexis shares traded daily (recently around 289117.64350453). Codexis's SIR currently stands at 16.55. In other words for every 100,000 Codexis shares traded daily on the market, roughly 16550 shares are currently held short.

However Codexis's short interest can also be evaluated against the total number of Codexis shares, or, against the total number of tradable Codexis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codexis's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Codexis shares in existence, roughly 80 shares are currently held short) or 0.0834% of the tradable shares (for every 100,000 tradable Codexis shares, roughly 83 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Codexis.

Find out more about how you can short Codexis stock.

Codexis share dividends

We're not expecting Codexis to pay a dividend over the next 12 months.

Codexis share price volatility

Over the last 12 months, Codexis's shares have ranged in value from as little as $8.43 up to $18.87. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Codexis's is 0.8235. This would suggest that Codexis's shares are less volatile than average (for this exchange).

Codexis overview

Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Frequently asked questions

• What percentage of Codexis is owned by insiders or institutions?

  Currently 3.447% of Codexis shares are held by insiders and 89.244% by institutions.

• How many people work for Codexis?

  Latest data suggests 161 work at Codexis.

• When does the fiscal year end for Codexis?

  Codexis's fiscal year ends in December.

• Where is Codexis based?

  Codexis's address is: 200 Penobscot Drive, Redwood City, CA, United States, 94063

• What is Codexis's ISIN number?

  Codexis's international securities identification number is: US1920051067

• What is Codexis's CUSIP number?

  Codexis's Committee on Uniform Securities Identification Procedures number is: 192005106